February 1998

Commercialization of Antibody Pharmaceuticals, Capital Participation in U.S. Firm PDL

Toagosei recently acquired 44,568 shares in Protein Design Labs, Inc. (PDL) of the United States. PDL is a manufacturer that develops humanized antibodies. Based on this capital participation, PDL will conduct clinical tests inside the United States on humanized antibodies which Toagosei has developed, develop anticancer agents and other products, and seek approval from the Food and Drug Administration (FDA). These activities will lead to the further strengthening of Toagosei's pharmaceutical business.